A study of lapatinib in combination with oxaliplatin and capecitabine in early HER-2 overexpressing oesophageal and gastric cancers.
Phase of Trial: Phase IV
Latest Information Update: 11 May 2018
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms LEO
- 10 Jun 2017 Biomarkers information updated
- 20 Oct 2015 Results published in the British Journal of Cancer
- 06 May 2013 Accrual to date is 76% according to United Kingdom Clinical Research Network record.